How to Engineer Antibodies to Better Target and Destroy Disease

This patent describes a way to modify the tail end of an antibody so it binds more strongly to immune cells, helping the body fight off infections or cancer more effectively.

What it covers

The patent claims specific modifications to the Fc region of an antibody, which is the 'tail' part that tells the immune system what to do. By swapping specific amino acids at positions 239 and 332—specifically using aspartic acid (D) or glutamic acid (E)—the antibody is engineered to bind more tightly to a receptor called FcγRIIIa. This receptor is found on natural killer cells and other immune cells. When the antibody binds more tightly to these cells, it triggers a stronger immune response, making the antibody much better at flagging and destroying target cells like cancer cells.

What it doesn't cover

• —Does not cover antibodies that do not contain the specific 239 and 332 amino acid substitutions.
• —Does not cover naturally occurring, non-engineered Fc regions.
• —Does not cover methods of treating patients, only the genetic material and production methods for the modified antibodies.
• —Does not cover Fc variants that use different amino acid positions for binding enhancement.

The clever bit

The inventors realized that by precisely tuning the electrostatic charge at two specific spots on the Fc region, they could dramatically increase affinity for the FcγRIIIa receptor without destabilizing the entire antibody structure.

Why it matters

This technology is a cornerstone of modern immunotherapy. By making antibodies 'stickier' to immune cells, drug developers can create treatments that require lower doses to be effective. This is essential for developing potent monoclonal antibodies used in oncology to help the patient's own immune system recognize and kill tumors.

Real-world examples

• 1.Monoclonal antibody cancer therapies
• 2.Immune-boosting protein therapeutics
• 3.Xencor's XmAb technology platform